LUMO
Income statement / Annual
Last year (2023), Lumos Pharma, Inc.'s total revenue was $2.05 M,
an increase of 34.67% from the previous year.
In 2023, Lumos Pharma, Inc.'s net income was -$34.03 M.
See Lumos Pharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$2.05 M
|
$1.52 M
|
$230,000.00
|
$168,000.00
|
$936,000.00
|
$1.21 M
|
$390,000.00
|
$3.53 M
|
$36.14 M
|
$165.95 M
|
Cost of Revenue |
$44,000.00 |
$49,000.00 |
$0.00 |
$0.00 |
$37,000.00 |
-$11.27 M |
$1.41 M |
$0.00 |
-$32.36 M |
-$6.64 M |
Gross Profit |
$2.01 M |
$1.47 M |
$230,000.00 |
$168,000.00 |
$899,000.00 |
$12.47 M |
-$1.02 M |
$3.53 M |
$68.50 M |
$172.59 M |
Gross Profit Ratio |
0.98 |
0.97 |
1 |
1 |
0.96 |
10.34 |
-2.61 |
1 |
1.9 |
1.04 |
Research and Development
Expenses |
$22.10 M
|
$17.86 M
|
$16.25 M
|
$9.21 M
|
$22.21 M
|
$45.69 M
|
$69.87 M
|
$93.30 M
|
$71.41 M
|
$35.69 M
|
General & Administrative
Expenses |
$16.57 M
|
$15.71 M
|
$15.33 M
|
$17.27 M
|
$23.87 M
|
$29.22 M
|
$31.73 M
|
$33.23 M
|
$30.69 M
|
$19.33 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$16.57 M
|
$15.71 M
|
$15.33 M
|
$17.27 M
|
$23.87 M
|
$29.22 M
|
$31.73 M
|
$33.23 M
|
$30.69 M
|
$19.33 M
|
Other Expenses |
$0.00 |
$91,000.00 |
$269,000.00 |
$6.47 M |
-$19,000.00 |
-$102,000.00 |
$371,000.00 |
$247,000.00 |
-$41,000.00 |
$60,000.00 |
Operating Expenses |
$38.67 M |
$33.56 M |
$31.58 M |
$26.47 M |
$46.07 M |
$63.64 M |
$73.27 M |
$94.28 M |
$69.75 M |
$48.38 M |
Cost And Expenses |
$38.67 M |
$33.56 M |
$31.58 M |
$26.47 M |
$46.07 M |
$63.64 M |
$73.27 M |
$94.28 M |
$69.75 M |
$48.38 M |
Interest Income |
$1.87 M |
$874,000.00 |
$12,000.00 |
$200,000.00 |
$2.23 M |
$2.03 M |
$616,000.00 |
$237,000.00 |
$78,000.00 |
$86,000.00 |
Interest Expense |
$0.00 |
$874,000.00 |
$0.00 |
$0.00 |
$50,000.00 |
$52,000.00 |
$119,000.00 |
$22,000.00 |
$105,000.00 |
$26,000.00 |
Depreciation &
Amortization |
$44,000.00
|
$49,000.00
|
$273,000.00
|
$584,000.00
|
$37,000.00
|
$1.15 M
|
$1.41 M
|
$2.08 M
|
$1.59 M
|
$1.10 M
|
EBITDA |
-$36.57 M
|
-$31.99 M
|
-$31.13 M
|
-$25.72 M
|
-$45.13 M
|
-$59.37 M
|
-$70.98 M
|
-$88.41 M
|
-$31.95 M
|
$118.76 M
|
EBITDA Ratio |
-17.83 |
-21.04 |
-136.29 |
-156.57 |
-45.86 |
-50.17 |
-186.87 |
-25.74 |
-0.93 |
0.71 |
Operating Income Ratio
|
-17.85
|
-21.04
|
-136.29
|
-156.57
|
-48.22
|
-51.77
|
-186.87
|
-25.74
|
-0.93
|
0.71
|
Total Other
Income/Expenses Net |
$2.55 M
|
$965,000.00
|
$281,000.00
|
$6.67 M
|
$35.43 M
|
$1.88 M
|
$371,000.00
|
$247,000.00
|
-$41,000.00
|
$60,000.00
|
Income Before Tax |
-$34.06 M |
-$31.08 M |
-$31.07 M |
-$19.64 M |
-$42.98 M |
-$60.56 M |
-$72.51 M |
-$90.51 M |
-$33.64 M |
$117.63 M |
Income Before Tax Ratio
|
-16.61
|
-20.4
|
-135.07
|
-116.88
|
-45.92
|
-50.22
|
-185.92
|
-25.67
|
-0.93
|
0.71
|
Income Tax Expense |
-$29,000.00 |
-$13,000.00 |
-$636,000.00 |
-$13.97 M |
$12,000.00 |
-$6.97 M |
-$559,000.00 |
-$5.36 M |
$6.74 M |
$14.78 M |
Net Income |
-$34.03 M |
-$31.06 M |
-$30.43 M |
-$5.66 M |
-$42.99 M |
-$53.60 M |
-$71.95 M |
-$85.16 M |
-$40.38 M |
$102.86 M |
Net Income Ratio |
-16.59 |
-20.4 |
-132.3 |
-33.71 |
-45.93 |
-44.44 |
-184.49 |
-24.15 |
-1.12 |
0.62 |
EPS |
-4.18 |
-3.71 |
-3.65 |
-0.84 |
-297.07 |
-12.97 |
-20.69 |
-26.45 |
-12.71 |
31.05 |
EPS Diluted |
-4.18 |
-3.71 |
-3.65 |
-0.84 |
-297.07 |
-12.97 |
-20.69 |
-26.45 |
-12.71 |
27.81 |
Weighted Average Shares
Out |
$8.15 M
|
$8.37 M
|
$8.33 M
|
$6.78 M
|
$144,709.00
|
$4.13 M
|
$3.48 M
|
$3.22 M
|
$3.18 M
|
$3.09 M
|
Weighted Average Shares
Out Diluted |
$8.15 M
|
$8.37 M
|
$8.33 M
|
$6.78 M
|
$144,709.00
|
$4.13 M
|
$3.48 M
|
$3.22 M
|
$3.18 M
|
$3.45 M
|
Link |
|
|
|
|
|
|
|
|
|
|